{"id":"afq056-with-l-dopa","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Somnolence"}]},"_chembl":{"chemblId":"CHEMBL2074776","moleculeType":"Small molecule","molecularWeight":"344.37"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"AFQ056 selectively blocks mGluR5 receptors on the postsynaptic side of glutamatergic synapses, reducing excitotoxic glutamate signaling that contributes to motor complications in Parkinson's disease. When combined with L-dopa (levodopa), the mGluR5 inhibition may enhance dopaminergic efficacy and reduce dyskinesias and motor fluctuations. This combination approach targets both the dopamine deficit and the secondary glutamatergic dysfunction characteristic of advanced Parkinson's disease.","oneSentence":"AFQ056 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator that reduces excessive glutamatergic signaling, combined with L-dopa to enhance dopaminergic activity in Parkinson's disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:21:17.526Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease with motor complications (dyskinesias and motor fluctuations)"}]},"trialDetails":[{"nctId":"NCT01173731","phase":"PHASE2","title":"Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-10","conditions":"Parkinson Disease, Dyskinesia, Drug-Induced, Levodopa","enrollment":66},{"nctId":"NCT01092065","phase":"PHASE2","title":"Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-03","conditions":"Parkinson's Disease","enrollment":23},{"nctId":"NCT01491932","phase":"PHASE2","title":"Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Dyskinesias, Parkinson Disease, Movement Disorders","enrollment":129},{"nctId":"NCT01491529","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-04","conditions":"Dyskinesias, Parkinson Disease, Movement Disorders","enrollment":154},{"nctId":"NCT01385592","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-11","conditions":"Dyskinesias, Parkinson Disease, Movement Disorders","enrollment":78},{"nctId":"NCT00986414","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-09","conditions":"Parkinson Disease, Dyskinesias","enrollment":260},{"nctId":"NCT00888004","phase":"PHASE2","title":"Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-03","conditions":"Parkinson's Disease, L-dopa Induced Dyskinesia","enrollment":28},{"nctId":"NCT00582673","phase":"PHASE2","title":"Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-10","conditions":"Parkinson's Disease","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AFQ056 with L-dopa","genericName":"AFQ056 with L-dopa","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AFQ056 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator that reduces excessive glutamatergic signaling, combined with L-dopa to enhance dopaminergic activity in Parkinson's disease. Used for Parkinson's disease with motor complications (dyskinesias and motor fluctuations).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}